Health
First human trial of Oxford COVID-19 vaccine shows promise – Reuters
An experimental vaccine being developed by AstraZeneca and Oxford University against the new coronavirus produced an immune response in early-stage clinical trials, data showed on Monday, preserving hopes it could be in use by the end of the year.
LONDON (Reuters) – An experimental vaccine being developed by AstraZeneca and Oxford University against the new coronavirus produced an immune response in early-stage clinical trials, data showed on Monday, preserving hopes it could be in use by the end of the year.
The vaccine, called AZD1222, has been described by the World Health Organization’s chief scientist as the leading candidate in a global race to halt a pandemic that has killed more than 600,000 people.
More than 150 possible vacc…
-
General20 hours agoVote counting begins for Townsville mayoral by-election
-
General22 hours agoThree NT residents charged with fraud over alleged $71 million Defence contract scheme
-
Business12 hours agoNvidia’s quiet move into quantum computing could reshape the next frontier of AI
-
Business10 hours ago3 US dividend stocks that can boost an ASX retirement portfolio